Funding for prostate cancer research


Tuesday, 22 April, 2014

Funding of $3.25 million is available from the Prostate Cancer Foundation of Australia (PCFA) and the Movember Foundation for prostate cancer research.

The 2014 Movember Foundation Revolutionary Team Award 3 (MRTA3) will provide funding over three years to support a translational research team collaborate and progress scientific and clinical research to improve the testing and treatment of prostate cancer.

Expressions of Interest are initially being sought and short-listed teams will be advised to develop their ideas into a full proposal.

Associate Professor Anthony Lowe, Chief Executive Officer at PCFA, said that transdisciplinary team efforts and innovative research hold the key to transforming the way we manage patients with localised prostate cancer and improve their quality of life.

The MRTA3 is part of PCFA’s National Research Program, the largest competitive prostate cancer research program established by a not-for-profit organisation.

The deadline for all Expressions of Interest is 5.00 pm on Friday 9 May 2014.

Further details about the MRTA3 can be found here

The Prostate Cancer Foundation of Australia is dedicated to reducing the impact of prostate cancer on Australian men, their partners, families and the wider community. The foundation receives government funding for specific projects and relies on donations and partnerships with organisations such as the Movember Foundation to carry out its work.

An independent global charity, Movember is responsible for the sprouting of millions of moustaches around the world during November each year. With their ‘moes’ men raise funds and generate awareness for prostate and testicular cancer and mental health

Related News

MV Hondius passengers return to Australia under strict infection control measures

The Australian CDC has provided an update on hantavirus risk to Australians and infection...

$96m RNA Research and Manufacturing Facility opens in NSW

The new 4500 sqm RNA Research and Manufacturing Facility within the Macquarie University...

Cartherics and Catalent announce enhanced partnership

To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd